Archive · CNBC Markets
J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.
ZAZTEK archives the headline, summary and publication date so the story stays findable. The full article remains the publisher's. Read it at CNBC Markets →